An abstract presented at the 2026 European Respiratory Society International Congress links semaglutide use in patients with type 2 diabetes to fewer exacerbations in asthma (38% reduction) and COPD (21% reduction). Other GLP-1 receptor agonists like exenatide and dulaglutide also showed exacerbation reductions. The associations persisted regardless of weight or glycemic changes, suggesting possible direct lung anti-inflammatory effects.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.